Loading quotes...

Forecast

The analysts' average price target is €157.12 (+1.07%). The median is €160.69 (+3.36%).

Buy
  14
Hold
  9
Sell
  0

  • Masimo rises after Danaher acquisition announced, highlighted by Baron Discovery Fund

    Baron Discovery Fund noted that Masimo outperformed after Danaher announced a deal to acquire Masimo at a 38% premium, calling it a special situation driven by an activist investor. The fund discussed Masimo's non-invasive patient monitoring technologies and said the situation worked out well for its performance. Masimo closed May 6 at $178.49, has a $9.35 billion market cap, and saw hedge fund holdings rise to 40 portfolios at year-end. » More on finance.yahoo.com


  • Masimo Corporation resurfaces after consumer divestiture with improving margins and recurring revenue

    Masimo Corporation is undergoing a turnaround after divesting its consumer segment in 2025 and refocusing on hospital patient monitoring. The company benefits from high-margin consumables driving recurring revenue, reported continuing-operations revenue growth of about 8% year‑over‑year, and operating margins rebounding toward ~27% with a path to 30% by 2028. A backlog above $500 million and high single-digit growth visibility support the thesis, while valuation remains discounted, leaving analysts projecting 24% to potentially over 50% upside with stronger execution over the next 12–18 months. » More on finance.yahoo.com


  • Bridger Management exits Masimo stake before $9.9 billion acquisition sparks 34% rally

    Bridger Management disclosed it sold its entire Masimo holding, cutting 47,841 shares and reducing its position by about $7.06 million. The sale followed a weak quarter and a roughly 12% pullback in the stock. Weeks later Masimo agreed to be acquired at $180 per share in a deal valuing the company at about $9.9 billion, driving an approximate 34% one‑day surge. The filing shows Bridger’s portfolio remains concentrated in large-cap, cash-generating names, leaving less exposure to event-driven upside like the Masimo takeover. » More on finance.yahoo.com

Historical dividends Dividends

All dividend metrics All metrics
In 2012, Masimo has already paid €0.77 in dividends. The last payout was in December 2012.

Financials

In the last quarter, Masimo had revenue of €350.34M and net profit of €49.57M
(EUR) April 2026
YoY
Revenue 350.34M -
Gross profit 217.7M -
Net profit 49.57M -
EBITDA 74.22M -

Fundamentals

Metric Value
Market capitalization
€8.41B
Number of shares
52.37M
52-week high/low
€160.68 - €112.43
Dividends No
Beta
1.18
P/E ratio
124.97
PEG ratio
0.49
P/B ratio
11.91
P/S ratio
6.05

Company profile

Masimo Corporation develops, manufactures, and markets noninvasive monitoring technologies and hospital automation solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry. It also provides Masimo rainbow SET platform that includes rainbow SET Pulse CO-Oximetry products that noninvasively monitor hemoglobin species, including oxygen saturation, pulse rate, perfusion index, pleth variability index, and respiration rate from the pleth; noninvasively monitor hemoglobin concentration, and carboxyhemoglobin and methemoglobin; monitor arterial oxygen saturation and acoustic respiration rate; and calculates oxygen content and oxygen reserve index. It offers SedLine brain function monitoring technology to measure the brain's electrical activity by detecting EEG signals; capnography and gas monitoring products comprising external plug-in-and-measure capnography and gas analyzers, integrated modules, handheld capnograph and capnometer devices, and capnography sampling lines; O3 regional oximetry for tissue oxygen saturation measurement; and hemodynamic monitoring solutions. Its Masimo Hospital Automation platform includes Patient SafetyNet, Patient SafetyNet surveillance, Kite, UniView, Replica, UniView : 60, and MyView. It offers connectivity devices; and nasal high flow ventilation and neuromodulation solutions. It provides its products through direct sales force, distributors, and original equipment manufacturers partners to hospitals, emergency medical service and home care providers, long-term care facilities, physician offices, veterinarians, and consumers; and non-medical/consumer products through e-commerce site, masimopersonalhealth.com. The company was incorporated in 1989 and is headquartered in Irvine, California.

Name
Masimo
CEO
Catherine Szyman
Headquarters Irvine, ca
Luxembourg
Website
Sector
Utilities
Industry
Health Care Equipment & Supplies
IPO
07/19/2012
Employees 7,500

Ticker symbols

Exchange Symbol
NASDAQ
MASI
London Stock Exchange
0JZ2.L
Frankfurt
3M4.F
DĂĽsseldorf
3M4.DU
London
0JZ2.L
SIX
3M4.SW
MĂĽnchen
3M4.MU
🍪

Parqet  uses cookies. Learn more